Skip to main content
Top
Published in: BMC Women's Health 1/2019

Open Access 01-12-2019 | Iron Deficiency | Research article

Economic burden of symptomatic iron deficiency – a survey among Swiss women

Authors: Patricia R. Blank, Yuki Tomonaga, Thomas D. Szucs, Matthias Schwenkglenks

Published in: BMC Women's Health | Issue 1/2019

Login to get access

Abstract

Background

Symptomatic iron deficiency (ID) is a disorder affecting 10–20% of menstruating women. ID is diagnosed by measuring serum ferritin, a protein helping to store iron in the body. A deeper understanding of the association between ID and its societal and economic burden is relevant for patients, physicians, health care decision makers.

Methods

An online household survey was carried out among Swiss women aged 18–50 years suffering from debilitating symptoms due to ID. The data was population-weighted for age and region. The costs of misdiagnosis and the ID-related economic burden (i.e. days of sick leave) from productivity losses on the labor market were determined and extrapolated to the Swiss population. Furthermore, the patient burden was assessed based on quality of life daily measurements.

Results

The total sample included 1010 women who received an ID diagnosis with a blood test in the last 2 years (mean age: 33.5 years). Most named symptoms were “being tired or exhausted” (96.4%) and reduced physical energy level (41.0%). In total, 354 (35.0% of the total sample) patients received an initial diagnosis other than ID. Of those, 46.8% were treated prior to the ID diagnosis with a pharmacological medical therapy or psychotherapy. Extrapolating these numbers to the Swiss female population aged 18–50 years, the direct medical costs would be CHF 78 million (assuming an annual ID incidence of ID diagnosis of 9.5%). On average, 28.5% of participants in the work-force had to take sick leave due to ID symptoms within a period of 2 years (mean: 5.2 days, i.e. 2.6 days/year). The estimated annual indirect costs in Switzerland would be CHF 33 million (human capital approach) or CHF 26 million (friction cost method), respectively. Being exhausted and impaired concentration appear to be the most important factors negatively impacting daily living and hence quality of life.

Conclusion

The societal and economic burden among women due to debilitating symptoms of ID in Switzerland is substantial. Timely, correct diagnosis and treatment of ID may contribute to reducing this burden. Further studies are needed in this area to validate our results.
Literature
1.
go back to reference Who. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015. Who. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015.
2.
go back to reference Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, Pena-Rosas JP, Bhutta ZA, Ezzati M. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population-representative data. Lancet Glob Health. 2013;1(1):e16–25.CrossRefPubMedCentralPubMed Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, Pena-Rosas JP, Bhutta ZA, Ezzati M. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population-representative data. Lancet Glob Health. 2013;1(1):e16–25.CrossRefPubMedCentralPubMed
3.
go back to reference Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. Jama. 1997;277(12):973–6.CrossRefPubMed Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. Jama. 1997;277(12):973–6.CrossRefPubMed
4.
go back to reference Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. Bmj. 2003;326(7399):1124.CrossRefPubMedCentralPubMed Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. Bmj. 2003;326(7399):1124.CrossRefPubMedCentralPubMed
5.
go back to reference Hercberg S, Preziosi P, Galan P. Iron deficiency in Europe. Public Health Nutr. 2001;4(2B):537–45.CrossRefPubMed Hercberg S, Preziosi P, Galan P. Iron deficiency in Europe. Public Health Nutr. 2001;4(2B):537–45.CrossRefPubMed
6.
go back to reference Beck KL, Conlon CA, Kruger R, Coad J. Dietary determinants of and possible solutions to iron deficiency for young women living in industrialized countries: a review. Nutrients. 2014;6(9):3747–76.CrossRefPubMedCentralPubMed Beck KL, Conlon CA, Kruger R, Coad J. Dietary determinants of and possible solutions to iron deficiency for young women living in industrialized countries: a review. Nutrients. 2014;6(9):3747–76.CrossRefPubMedCentralPubMed
7.
go back to reference Pena-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015;10:CD009997. Pena-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015;10:CD009997.
8.
go back to reference Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014;19(2):164–74.PubMedPubMedCentral Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014;19(2):164–74.PubMedPubMedCentral
9.
go back to reference Polin V, Coriat R, Perkins G, Dhooge M, Abitbol V, Leblanc S, Prat F, Chaussade S. Iron deficiency: from diagnosis to treatment. Di g Liver Dis. 2013;45(10):803–9.CrossRef Polin V, Coriat R, Perkins G, Dhooge M, Abitbol V, Leblanc S, Prat F, Chaussade S. Iron deficiency: from diagnosis to treatment. Di g Liver Dis. 2013;45(10):803–9.CrossRef
10.
go back to reference Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387(10021):907–16.CrossRefPubMed Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387(10021):907–16.CrossRefPubMed
11.
go back to reference SBM SMB: Orale oder parenterale Behandlung des Eisenmangels. 2014. SBM SMB: Orale oder parenterale Behandlung des Eisenmangels. 2014.
15.
go back to reference council SGSf: Bundesgesetz über den Datenschutz / Swiss law for data protection. In.; 2014. council SGSf: Bundesgesetz über den Datenschutz / Swiss law for data protection. In.; 2014.
16.
go back to reference Ministry F: Deutsches Bundesdatenschutzgesetz (BDSG) / German law for data protection 2003. Ministry F: Deutsches Bundesdatenschutzgesetz (BDSG) / German law for data protection 2003.
17.
go back to reference Simon Wieser YT, Marco Riguzzi, Barbara Fischer, Harry Telser, Mark Pletscher, Klaus Eichler, Melanie Trost, Matthias Schwenkglenks: Die Kosten der nichtübertragbaren Krankheiten in der Schweiz. 2014, Vertragsnummer 13.006625. Simon Wieser YT, Marco Riguzzi, Barbara Fischer, Harry Telser, Mark Pletscher, Klaus Eichler, Melanie Trost, Matthias Schwenkglenks: Die Kosten der nichtübertragbaren Krankheiten in der Schweiz. 2014, Vertragsnummer 13.006625.
18.
go back to reference Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. The hidden cost of chronic fatigue to patients and their families. BMC Health Serv Res. 2010;10:56.CrossRefPubMedCentralPubMed Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. The hidden cost of chronic fatigue to patients and their families. BMC Health Serv Res. 2010;10:56.CrossRefPubMedCentralPubMed
19.
go back to reference Tomonaga Y, Haettenschwiler J, Hatzinger M, Holsboer-Trachsler E, Rufer M, Hepp U, Szucs TD. The economic burden of depression in Switzerland. PharmacoEconomics. 2013;31(3):237–50.CrossRefPubMed Tomonaga Y, Haettenschwiler J, Hatzinger M, Holsboer-Trachsler E, Rufer M, Hepp U, Szucs TD. The economic burden of depression in Switzerland. PharmacoEconomics. 2013;31(3):237–50.CrossRefPubMed
20.
go back to reference Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79.CrossRefPubMed Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79.CrossRefPubMed
25.
go back to reference Ademi Z, Tomonaga Y, van Stiphout J, Glinz D, Gloy V, Raatz H, Bucher HC, Schwenkglenks M. Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. Swiss Med Wkly. 2018;148:w14626.PubMed Ademi Z, Tomonaga Y, van Stiphout J, Glinz D, Gloy V, Raatz H, Bucher HC, Schwenkglenks M. Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. Swiss Med Wkly. 2018;148:w14626.PubMed
26.
go back to reference Breyer F, P Zweifel und, F Kifmann Gesundheitsökonomie 5. Berlin: Springer Verlag; 2005. Breyer F, P Zweifel und, F Kifmann Gesundheitsökonomie 5. Berlin: Springer Verlag; 2005.
27.
go back to reference Zhang W, Anis AH. The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol. 2011;30(Suppl 1):S25–32.CrossRefPubMed Zhang W, Anis AH. The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol. 2011;30(Suppl 1):S25–32.CrossRefPubMed
28.
go back to reference Koopmanschap MAea: J Health Econ 1995, 14:171–189. Koopmanschap MAea: J Health Econ 1995, 14:171–189.
29.
go back to reference van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89–91.CrossRefPubMed van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89–91.CrossRefPubMed
30.
go back to reference Schweiz BSLd: Ständige Wohnbevölkerung nach Alter, Geschlecht und Staatsangehörigkeitskategorie, am 31.12.2014. Schweiz BSLd: Ständige Wohnbevölkerung nach Alter, Geschlecht und Staatsangehörigkeitskategorie, am 31.12.2014.
32.
go back to reference Arthur CK, Isbister JP. Iron deficiency. Misunderstood, misdiagnosed and mistreated. Drugs. 1987;33(2):171–82.CrossRefPubMed Arthur CK, Isbister JP. Iron deficiency. Misunderstood, misdiagnosed and mistreated. Drugs. 1987;33(2):171–82.CrossRefPubMed
33.
go back to reference Kostopoulou O, Delaney BC, Munro CW. Diagnostic difficulty and error in primary care--a systematic review. Fam Pract. 2008;25(6):400–13.CrossRefPubMed Kostopoulou O, Delaney BC, Munro CW. Diagnostic difficulty and error in primary care--a systematic review. Fam Pract. 2008;25(6):400–13.CrossRefPubMed
34.
go back to reference Levin HM. A benefit-cost analysis of nutritional programs for Anemia reduction. World Bank Res Obs. 1986;1(2):219–45.CrossRef Levin HM. A benefit-cost analysis of nutritional programs for Anemia reduction. World Bank Res Obs. 1986;1(2):219–45.CrossRef
Metadata
Title
Economic burden of symptomatic iron deficiency – a survey among Swiss women
Authors
Patricia R. Blank
Yuki Tomonaga
Thomas D. Szucs
Matthias Schwenkglenks
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Iron Deficiency
Published in
BMC Women's Health / Issue 1/2019
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-019-0733-2

Other articles of this Issue 1/2019

BMC Women's Health 1/2019 Go to the issue